Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-blind, Dose-ranging Study to Evaluate GSK573719 in Combination With Fluticasone Furoate, Fluticasone Furoate Alone, and an Active Control of Fluticasone Furoate/Vilanterol Combination in Subjects With Asthma
Brief Summary: Brief Summary: The purpose of this study is to characterize the dose response of GSK573719 in combination with Fluticasone furoate 100mcg in patients with asthma. Treatment with inhaled Fluticasone furoate and Fluticasone furoate/Vilanterol are included as an active control.

Detailed Description: Long acting muscarinic receptor antagonists (anti-cholinergic bronhcodilator) exert their effects via distinct and complementary bronchodilator mechanisms on large and small airways. Most of the experience with older anti-cholinergics had been with acute use and little is known about their effect in chronic use in asthma. This is a multicenter, randomized, double-blind, crossover study to evaluate 5 doses of inhaled GSK573719 inhaled over 14 days in patients with asthma. Fluticasone furoate (100 mcg) and Fluticasone furoate/Vilanterol (100/59mcg) will be included as an active comparator. Each eligible subject will receive a sequence of 3 of 7 potential treatments for a total of 3 treatment periods per subject. The total duration of subject participation is approximately 14 weeks.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Vilanterol | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Vilanterol | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Vilanterol | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate 100mcg; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Arm 1, Arm 2, Arm 3
B: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Furoate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate Inhalation Powder, Other: Placebo Inhalation Powder 1 | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Propionate Inhalation Powder; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 1; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 2; Assigned to Arm(s): Fluticasone Furoate, Fluticasone Furoate/Vilanterol
C: Arm Label: GW642444M 25mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 50mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 100mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 200mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 400mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Intervention Type: DRUG; Name: GW642444M for 14 days; Assigned to Arm(s): GW642444M 100mcg, GW642444M 200mcg, GW642444M 25mcg, GW642444M 400mcg, GW642444M 50mcg
D: Arm Label: Fluticasone Furoate (FF); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF | Arm Label: Fluticasone Furoate /Vilanterol (VI); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/VI | Arm Label: Fluticasone Furoate/GSK573719; Type: EXPERIMENTAL; Interventions: Drug: FF/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF; Assigned to Arm(s): Fluticasone Furoate (FF) | Intervention Type: DRUG; Name: FF/VI; Assigned to Arm(s): Fluticasone Furoate /Vilanterol (VI)

Answer: D